Immunophenotypic, cytogenetic and molecular findings of core binding factor leukemia patients
| BMMNC Asp816Val and Asp816Tyr Status . | Patient Sex/Age . | Surface Antigens . | FAB . | Karyotype . | ||||
|---|---|---|---|---|---|---|---|---|
| CD13 . | CD33 . | CD34 . | CD117 . | HLADR . | ||||
| Asp816Val | 3 F/28 | 36, 7 | ND | 46, 9 | ND | 47, 4 | AML-M2 | 46,XX,t(8;14;21) |
| and | 4 F/72 | 48, 6 | 68 | 29 | 21, 9 | 60 | AML-M2 | 46,XX,t(8;21)(q22;q22) |
| Asp816Tyr | 6 M/26 | 88, 9 | 88, 7 | 87, 4 | 87, 2 | 95 | AML-M2 | 45,X,-Y,t(8;21)(q22;q22){15};46XYt(8;21)(q22;q22){17};46XY{5} |
| negative | 7 F/31 | 78 | 72 | 68 | 50 | 60 | AML-M2 | 46,XX,t(8;21)(q22;q22){40} |
| 9 M/32 | 21 | 53, 5 | 56, 8 | 57 | ND | AML-M2 | 45,X,-Y,t(8;21)(q22;q22) | |
| 10 F/42 | 79, 7 | 28, 9 | 58, 1 | ND | 69, 4 | AML-M4Eo | 46,XX,inv(16)(p13;q22){20} | |
| 11 M/45 | 80 | 71, 4 | 65, 2 | ND | 78, 3 | AML-M4Eo | 47,XY,inv(16)(p13;q22),+21{20} | |
| 12 F/59 | 84 | 79 | 1 | 60 | 61 | AML-M4Eo | 46,XX,inv(16)(p13;q22){19};46XX{1} | |
| 14 F/42 | 81, 1 | 73 | 30, 7 | 20 | 75, 3 | AML-M4Eo | 46,XX,inv(16)(p13;q22){32};46XX{2} | |
| Asp816Val | 2 M/65 | 15, 3 | 21, 4 | 52, 9 | ND | ND | AML-M2 | 47,XY,+4,t(8;21)(q22;q22) |
| positive | 5 M/16 | 77, 2 | 62, 1 | 62, 9 | 39, 7 | 73, 2 | AML-M2 | 46,XY;46,XY,t(8;21)(q22;q22);47,XY,+13,t(8;21)(q22;q22) |
| 8 M/40 | 93, 7 | 95 | 33, 5 | 48 | 91, 2 | AML-M2 | 46,XY,t(2;8;21)(q24;q22;q22) | |
| 13 M/55 | 89, 8 | 56, 5 | 61, 7 | 40 | 10, 5 | AML-M4Eo | 46,XY;inv(16)(p13;q22) | |
| 15 M/53 | 81, 1 | 78, 6 | 66, 9 | 73, 8 | 44 | AML-M4Eo | 46,XY,inv(16)(p13;q22) | |
| Asp816Tyr | 1 M/47 | 87 | 70 | 87 | 23 | 94 | AML-M2 | 47,XY,+4,t(8;21)(q22;q22) |
| positive | ||||||||
| BMMNC Asp816Val and Asp816Tyr Status . | Patient Sex/Age . | Surface Antigens . | FAB . | Karyotype . | ||||
|---|---|---|---|---|---|---|---|---|
| CD13 . | CD33 . | CD34 . | CD117 . | HLADR . | ||||
| Asp816Val | 3 F/28 | 36, 7 | ND | 46, 9 | ND | 47, 4 | AML-M2 | 46,XX,t(8;14;21) |
| and | 4 F/72 | 48, 6 | 68 | 29 | 21, 9 | 60 | AML-M2 | 46,XX,t(8;21)(q22;q22) |
| Asp816Tyr | 6 M/26 | 88, 9 | 88, 7 | 87, 4 | 87, 2 | 95 | AML-M2 | 45,X,-Y,t(8;21)(q22;q22){15};46XYt(8;21)(q22;q22){17};46XY{5} |
| negative | 7 F/31 | 78 | 72 | 68 | 50 | 60 | AML-M2 | 46,XX,t(8;21)(q22;q22){40} |
| 9 M/32 | 21 | 53, 5 | 56, 8 | 57 | ND | AML-M2 | 45,X,-Y,t(8;21)(q22;q22) | |
| 10 F/42 | 79, 7 | 28, 9 | 58, 1 | ND | 69, 4 | AML-M4Eo | 46,XX,inv(16)(p13;q22){20} | |
| 11 M/45 | 80 | 71, 4 | 65, 2 | ND | 78, 3 | AML-M4Eo | 47,XY,inv(16)(p13;q22),+21{20} | |
| 12 F/59 | 84 | 79 | 1 | 60 | 61 | AML-M4Eo | 46,XX,inv(16)(p13;q22){19};46XX{1} | |
| 14 F/42 | 81, 1 | 73 | 30, 7 | 20 | 75, 3 | AML-M4Eo | 46,XX,inv(16)(p13;q22){32};46XX{2} | |
| Asp816Val | 2 M/65 | 15, 3 | 21, 4 | 52, 9 | ND | ND | AML-M2 | 47,XY,+4,t(8;21)(q22;q22) |
| positive | 5 M/16 | 77, 2 | 62, 1 | 62, 9 | 39, 7 | 73, 2 | AML-M2 | 46,XY;46,XY,t(8;21)(q22;q22);47,XY,+13,t(8;21)(q22;q22) |
| 8 M/40 | 93, 7 | 95 | 33, 5 | 48 | 91, 2 | AML-M2 | 46,XY,t(2;8;21)(q24;q22;q22) | |
| 13 M/55 | 89, 8 | 56, 5 | 61, 7 | 40 | 10, 5 | AML-M4Eo | 46,XY;inv(16)(p13;q22) | |
| 15 M/53 | 81, 1 | 78, 6 | 66, 9 | 73, 8 | 44 | AML-M4Eo | 46,XY,inv(16)(p13;q22) | |
| Asp816Tyr | 1 M/47 | 87 | 70 | 87 | 23 | 94 | AML-M2 | 47,XY,+4,t(8;21)(q22;q22) |
| positive | ||||||||
ND, not determined; BMMNC, bone marrow mononuclear cell.